🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being described as a "major milestone" in the effort against increasingly resistant strains of the infection, according to researchers.

A Worldwide Challenge

The sexually transmitted infection are increasing around the world, with estimates suggesting more than 82 million instances each year. Especially elevated rates are observed in Africa and nations within the World Health Organization's designated area, which spans from China and Mongolia to New Zealand. In England, cases have reached a record high, while rates across Europe in 2023 were three times higher compared to the rates from 2014.

“The approval of novel therapies for gonorrhoea is an critical and opportune step in the reality of rising global incidence, the spread of superbugs and the highly restricted treatment choices currently available.”

Medical experts are deeply concerned about the surge in treatment-resistant strains. The WHO has designated it as a "priority pathogen". A tracking program found that resistance to primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Drugs Receive Authorization

Zoliflodacin, alternatively called a brand name, was cleared by the American regulatory agency in recent days for combating gonorrhoea. This STI can lead to major issues, including the inability to conceive. Researchers hope that targeted use of this new drug will help slow the emergence of superbugs.

Gepotidacin, created by the drugmaker GlaxoSmithKline, also received approval in close succession. This drug, which is employed against urinary tract infections, was proven in research to be effective against drug-resistant strains of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin emerged from a unique collaborative effort for antibiotic development. The charitable organization GARDP partnered with the pharmaceutical company Innoviva to see it through.

“This authorization represents a major breakthrough in the treatment of highly resistant gonorrhoea, which until now has been outpacing medical innovation.”

Research Study Outcomes and Global Access

According to results detailed in a major medical journal, the new drug cured over nine in ten of uncomplicated infections. This places it at an comparable level with the current standard treatment, which involves an injection and a pill. The research included over 900 patients from various regions including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, GARDP has the rights to make available and distribute the drug in many low-income and middle-income countries.

Clinicians treating patients have expressed positive views. Having a one-pill regimen like this is described as a "game-changer" for gonorrhoea control. This is deemed crucial to alleviate the strain of the illness for patients and to halt the transmission of extremely resistant gonorrhoea around the world.